Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$5.50 +1.5%	$4.57	$2.37 ▼ $5.72	$1.22B	2.53	780,549 shs	994,162 shs
HRTX Heron Therapeutics	$2.23 +1.4%	$2.05	$1.04 ▼ $3.73	$335.64M	1.18	2.17 million shs	1.08 million shs
PAHC Phibro Animal Health	$31.39 +4.2%	$24.06	$16.16 ▼ $31.53	$1.22B	0.75	218,752 shs	469,142 shs
TVTX Travere Therapeutics	$16.33 +6.7%	$16.44	$7.93 ▼ $25.29	$1.36B	0.72	1.62 million shs	2.10 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	+1.48%	+1.85%	+22.77%	+92.31%	+79.74%
HRTX Heron Therapeutics	+1.36%	+3.72%	+5.19%	+22.53%	-24.02%
PAHC Phibro Animal Health	+4.22%	+12.35%	+29.55%	+77.14%	+83.14%
TVTX Travere Therapeutics	+6.73%	+10.04%	+9.52%	+21.05%	+72.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CVAC CureVac	4.4976 of 5 stars	4.1	5.0	0.0	4.9	0.0	0.0	1.3
HRTX Heron Therapeutics	3.8222 of 5 stars	3.5	0.0	0.0	4.2	2.8	1.7	0.6
PAHC Phibro Animal Health	3.6762 of 5 stars	0.9	2.0	2.5	1.1	3.0	3.3	2.5
TVTX Travere Therapeutics	3.3236 of 5 stars	4.4	3.0	0.0	0.0	2.4	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	2.20	Hold	$6.83	24.24% Upside
HRTX Heron Therapeutics	3.00	Buy	$5.00	124.22% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-22.27% Downside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.14	96.83% Upside

Current Analyst Ratings Breakdown

Latest HRTX, TVTX, CVAC, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
7/1/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$30.00
6/26/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral	$12.00 ➝ $5.50
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/13/2025	CVAC CureVac	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $5.00
6/12/2025	CVAC CureVac	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
6/12/2025	CVAC CureVac	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/11/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$30.00
6/11/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$35.00 ➝ $32.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$579.18M	2.13	$0.89 per share	6.21	$3.36 per share	1.64
HRTX Heron Therapeutics	$144.29M	2.36	N/A	N/A	($0.22) per share	-10.14
PAHC Phibro Animal Health	$1.02B	1.25	$2.20 per share	14.25	$6.34 per share	4.95
TVTX Travere Therapeutics	$233.18M	6.22	N/A	N/A	$0.76 per share	21.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.92	5.98	N/A	N/A	35.44%	30.89%	25.54%	8/13/2025 (Estimated)
HRTX Heron Therapeutics	-$13.58M	-$0.06	N/A	N/A	N/A	-5.24%	N/A	-3.43%	8/5/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	40.24	14.95	0.50	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
TVTX Travere Therapeutics	-$321.55M	-$2.81	N/A	N/A	N/A	-82.88%	-1,179.73%	-41.10%	7/30/2025 (Estimated)

Latest HRTX, TVTX, CVAC, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	N/A	TVTX Travere Therapeutics	-$0.26	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	N/A	N/A	N/A	$38.08 million	N/A
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million
4/10/2025	Q4 2024	CVAC CureVac	-$0.14	-$0.15	-$0.01	-$0.15	$6.40 million	$15.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.53%	N/A	61.54%	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest HRTX, TVTX, CVAC, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.05	7.65	7.64
HRTX Heron Therapeutics	N/A	2.40	1.76
PAHC Phibro Animal Health	2.67	2.91	1.23
TVTX Travere Therapeutics	9.46	2.05	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
HRTX Heron Therapeutics	80.01%
PAHC Phibro Animal Health	99.34%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
HRTX Heron Therapeutics	5.86%
PAHC Phibro Animal Health	50.07%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	Optionable
HRTX Heron Therapeutics	300	152.56 million	143.62 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
TVTX Travere Therapeutics	460	88.81 million	85.08 million	Optionable

HRTX, TVTX, CVAC, and PAHC Headlines

Recent News About These Companies

109,542 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Penserra Capital Management LLC

July 8 at 5:37 AM | marketbeat.com

Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)

July 6, 2025 | insidermonkey.com

Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)

July 6, 2025 | msn.com

Q2 EPS Estimate for Travere Therapeutics Lowered by Analyst

July 4, 2025 | americanbankingnews.com

Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 815 Shares of Stock

July 3, 2025 | insidertrades.com

Q2 EPS Estimate for Travere Therapeutics Cut by Analyst

July 3, 2025 | marketbeat.com

Jula Inrig Sells 815 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

July 2, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

July 2, 2025 | prnewswire.com

1TVTX : Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews

July 2, 2025 | benzinga.com

Travere Therapeutics (NASDAQ:TVTX) Earns "Buy" Rating from HC Wainwright

July 2, 2025 | americanbankingnews.com

Travere Therapeutics (NASDAQ:TVTX) Given Buy Rating at HC Wainwright

July 1, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX - Morningstar

June 29, 2025 | morningstar.comM

Travere Therapeutics Inc News (TVTX) - Investing.com

June 27, 2025 | investing.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 23, 2025 | globenewswire.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Brokerages

June 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 22, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 16, 2025 | accessnewswire.comA

Equities Analysts Set Expectations for TVTX FY2025 Earnings

June 16, 2025 | marketbeat.com

What is HC Wainwright's Estimate for TVTX Q2 Earnings?

June 16, 2025 | marketbeat.com

Travere Therapeutics’ SWOT analysis: rare disease stock faces regulatory hurdles

June 15, 2025 | investing.com

Assenagon Asset Management S.A. Sells 116,999 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

June 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX, TVTX, CVAC, and PAHC Company Descriptions

CureVac NASDAQ:CVAC

$5.50 +0.08 (+1.48%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$5.44 -0.06 (-1.09%)

As of 07/9/2025 06:47 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Heron Therapeutics NASDAQ:HRTX

$2.23 +0.03 (+1.36%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$2.18 -0.04 (-2.02%)

As of 04:24 AM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Phibro Animal Health NASDAQ:PAHC

$31.39 +1.27 (+4.22%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$31.00 -0.39 (-1.24%)

As of 07/9/2025 07:56 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Travere Therapeutics NASDAQ:TVTX

$16.33 +1.03 (+6.73%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$16.32 0.00 (-0.03%)

As of 07/9/2025 07:08 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time